...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Intestinal research. >Current new challenges in the management of ulcerative colitis
【24h】

Current new challenges in the management of ulcerative colitis

机译：溃疡性结肠炎治疗中的新挑战

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract. Although the cause of UC is postulated to be multifactorial in nature, including genetic predisposition, epithelial barrier defects, dysregulation of immune responses, and environmental factors, the specific pathogenesis of UC is still incompletely understood. In the treatment of UC so far, a method of suppressing immunity and treating it has been mainstream. Immunosuppressant drugs, including thiopurines (azathioprine or 6-mercaptopurine), anti-tumor necrosis factor-α (anti-TNF-α) antibody (infliximab and adalimumab), and calcineurin inhibitor, can be used in treat patients with corticosteroid-dependent and/or corticosteroid-refractory moderate-to-severe UC. Recently, in addition to such a conventional therapeutic agent, golimumab, which is the first transgenic human monoclonal anti-TNF-α antibody to be fabricated, anti α-4/β-7 integrin antibody, and Janus kinase inhibitor have been reported to novel immunosuppressant therapy. Furthermore, other treatments with unique mechanisms different from immunosuppression, have also been suggested, including fecal microbiota transplantation and Indigo naturalis, which is a Chinese herbal medicine. We compared the features and efficacy of these new treatments. In this issue, the features and treatment options for these new treatments is reviewed.
机译：溃疡性结肠炎（UC）是胃肠道的慢性炎症。尽管假定UC的病因本质上是多因素的，包括遗传易感性，上皮屏障缺陷，免疫反应失调和环境因素，但UC的具体发病机理仍未完全了解。迄今为止，在UC的治疗中，抑制免疫力和对其进行治疗的方法已经成为主流。包括硫嘌呤（硫唑嘌呤或6-巯基嘌呤），抗肿瘤坏死因子-α（抗TNF-α）抗体（英夫利昔单抗和阿达木单抗）和钙调神经磷酸酶抑制剂在内的免疫抑制剂可用于治疗皮质类固醇依赖型和/或皮质类固醇难治性中度至重度UC。最近，除了这种常规的治疗剂外，据报道，戈利木单抗是第一个要制备的转基因人单克隆抗TNF-α抗体，抗α-4/β-7整联蛋白抗体和Janus激酶抑制剂是新型的。免疫抑制剂治疗。此外，还提出了其他具有不同于免疫抑制作用的独特机制的治疗方法，包括粪便微生物群移植和中草药靛蓝。我们比较了这些新疗法的功能和功效。在本期中，将对这些新疗法的功能和疗法选项进行综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号